Assessment of TDLN in murine tumour (mesothelioma, melanoma, pancreatic and colon adenocarcinoma) models following TDLN-targeted PD-L1 blockade, correlated with PD-1/PD-L1 interactions in TDLN of non-metastatic melanoma patients (see below). This evidence concerns the gene CD274 and melanoma.